Briacell Therapeutics Corp. Registered Shares o.N.

BriaCell Therapeutics shares fell about 55% in premarket trading to roughly $4.97 after the company announced a public capital raise of $30 million. The units are being offered at $5.59 per unit; each unit comprises a common share (or pre-funded warrant) and an immediately exercisable warrant with a $6.93 exercise price and a five-year term. Trading of the warrants under the ticker BCTXL is set to begin on January 14; the deal is expected to close on January 15 and is intended to cover working capital and general corporate purposes. » More on de.investing.com

BriaCell Therapeutics released results for the quarter ended October 31, 2025, and stated a loss per share of CAD 6.04. In the same quarter a year earlier, the result per share was -CAD 45.06. » More on finanzen.net

At the San Antonio Breast Cancer Symposium, BriaCell presented positive data on its immunotherapy Bria-IMT, after which the stock rose to $0.40 and reached a 52-week high. Interim analyses from the phase 3 trial (116 patients) showed good tolerability and median progression-free survival of 3.7–3.9 months; favorable NLR values and a positive DTH response were associated with longer survival. Researchers identified potential immunological biomarkers to predict response, the study was expanded to 79 US sites, and Bria-IMT has Fast Track status; top-line results are expected in H1 2026. Additionally, BriaCell announced a collaboration with the Memorial Sloan Kettering Cancer Center to further develop its platform. » More on de.investing.com